Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 2/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3256649 | 0.95 | L3MBTL1 (0.66) | L3MBTL1TDP1CYP2A6MEN1KMT2A | |
| SCHEMBL4961181 | 0.93 | L3MBTL1 (0.64) | L3MBTL1TDP1CYP2A6MEN1KMT2A | |
| SCHEMBL883731 | 0.89 | ATM (0.57) | L3MBTL1TDP1CYP2A6MEN1KMT2A | |
| SCHEMBL29403584 | 0.89 | ATM (0.57) | L3MBTL1TDP1CYP2A6MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3544868 | 0.87 | ATM (0.55) | L3MBTL1TDP1CYP2A6HRH1CHRNA7 | |
| SCHEMBL16606319 | 0.85 | CHRM2 (0.68) | L3MBTL1TDP1CYP2A6HRH1CHRNA7 | |
| SCHEMBL29485677 | 0.82 | CYP2A6 (0.76) | L3MBTL1TDP1CYP2A6HRH1CHRNA7 | |
| SCHEMBL2843094 | 0.82 | CYP2A6 (0.76) | L3MBTL1TDP1CYP2A6HRH1CHRNA7 | |
| SCHEMBL29485675 | 0.82 | TDP1 (0.80) | L3MBTL1TDP1CYP2A6HRH1CHRNA7 | |
| SCHEMBL724788 | 0.82 | TDP1 (0.80) | L3MBTL1TDP1CYP2A6HRH1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558965-A1 | NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-10-30 | — | — | EP | claimed |
| CN-110248933-A | Novel quinoline and isoquinoline derivatives for the treatment of pain and pain related disorders | 埃斯特韦制药股份公司 | 2019-09-17 | — | — | CN | claimed |
| WO-2018115064-A1 | NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2018-06-28 | — | — | WO | claimed |
| EP-3247705-B1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF AS NAMPT INHIBITORS | MILLENNIUM PHARM INC (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3558965-A1 | NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-10-30 | — | — | EP | disclosed |
| CN-110248933-A | Novel quinoline and isoquinoline derivatives for the treatment of pain and pain related disorders | 埃斯特韦制药股份公司 | 2019-09-17 | — | — | CN | disclosed |
| WO-2018115064-A1 | NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2018-06-28 | — | — | WO | disclosed |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| WO-2016118565-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-7772252-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772252-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7109215-B2 | Compounds possessing neuronal activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-09-19 | — | — | US | disclosed |
| US-20020013351-A1 | Compounds possessing neuronal activity | VERTEX PHARMACEUTICALS INCORPORATED | 2002-01-31 | — | — | US | disclosed |
| US-6268384-B1 | DO NOT BIND TO FKBP, AND WHICH DO NOT HAVE MULTI-DRUG RESISTANCE REVERSAL ACTIVITY. | VERTEX PHARMACEUTICALS INCORPORATED | 2001-07-31 | — | — | US | disclosed |
| EP-1007521-A1 | COMPOUNDS POSSESSING NEURONAL ACTIVITY | Vertex Pharmaceuticals Incorporated (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999010340-A1 | COMPOUNDS POSSESSING NEURONAL ACTIVITY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0551993-B1 | Pyrrolidine derivatives and process for preparing the same | SUMITOMO PHARMA (JP) | 1996-07-10 | — | — | EP | disclosed |
| US-5322952-A | Pyrrolidine derivatives and process for preparing the same | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-06-21 | — | — | US | disclosed |
| EP-0551993-A1 | Pyrrolidine derivatives and process for preparing the same | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NAMPT, NQO2, NNMT | L3MBTL1 2778/4885TDP1 1943/4885CYP2A6 2902/4885 |
| US-20020013351-A1 | Compounds possessing neuronal activity | BDNF, NGF, GAP43 | L3MBTL1 2987/4885TDP1 476/4885CYP2A6 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.